<DOC>
	<DOC>NCT00418171</DOC>
	<brief_summary>The primary objective of the study is to estimate the relative incidence among users of ziprasidone and olanzapine of non-suicide mortality.</brief_summary>
	<brief_title>Large Simple Trial (LST) Of Cardiovascular Safety Of Ziprasidone And Olanzapine- (Zodiac)</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Ziprasidone</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Patients newly treated for schizophrenia and those receiving continuing treatment will be eligible if the treating psychiatrist is ready to initiate a new antipsychotic medication, and would consider using either ziprasidone or olanzapine as an appropriate therapy. Male and female patients who meet all criteria listed below are eligible to be enrolled in this study: Diagnosed with schizophrenia Willing to provide information on at least one alternate contact person for study staff to contact regarding patient's whereabouts, should the patient be losttofollowup over the course of the study Progressive fatal disease of a life expectancy which prohibits them from participating in a one year research study Previously randomized to study medication and enrolled in this study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
</DOC>